Education
About Us
Working with TipRanks
Follow Us
XMAG - AI Analysis
Top Page
Defiance Large Cap ex-Mag 7 ETF (XMAG)
Rating:71Outperform
Price Target:
$25.00
Positive Factors
Strong Top Holdings
Several key positions, such as Broadcom and Oracle, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Technology, Financials, and Health Care, reducing reliance on any single industry.
Moderate Expense Ratio
The fund's expense ratio of 0.35% is relatively low, making it cost-effective compared to many actively managed funds.
Negative Factors
Overwhelming U.S. Exposure
With over 98% of assets in U.S. companies, the ETF lacks meaningful international diversification.
Underperforming Holdings
Some top holdings, such as Eli Lilly and Exxon Mobil, have shown weaker year-to-date performance, which could drag on returns.
Small Asset Base
The ETF's relatively low assets under management may lead to less liquidity and higher trading costs for investors.
XMAG vs. SPDR S&P 500 ETF (SPY)
AUM53.13M
RegionNorth America
Expense Ratio0.35%
Beta0.88
IssuerDefiance
Inception DateOct 21, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedBITA US 500 ex-Magnificent 7 Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume40,136
30 Day Avg. Volume25,242
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
25.32Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering496
XMAG Summary
The Defiance Large Cap ex-Mag 7 ETF (XMAG) is an investment fund that focuses on large-cap companies while excluding the seven biggest tech giants, often called the 'Mag 7.' This ETF includes well-known companies like Broadcom and JPMorgan Chase, offering exposure to diverse sectors such as financials, healthcare, and consumer goods. Investors might consider XMAG for balanced growth and diversification without heavy reliance on mega-cap tech stocks. However, a key risk is that the fund’s performance can still fluctuate with the broader market, as it includes companies from various industries.
How much will it cost me?The expense ratio for the Defiance Large Cap ex-Mag 7 ETF (XMAG) is 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed to exclude the 'Mag 7' tech giants, requiring more oversight and strategy. It’s designed for investors seeking a unique approach to large-cap stocks.
What would affect this ETF?XMAG's focus on excluding the 'Mag 7' tech giants could benefit from a shift in investor sentiment towards diversification and reduced reliance on mega-cap tech stocks. Positive drivers include potential growth in sectors like financials and healthcare, which are significant holdings, and stability from its broad exposure to U.S. large-cap companies. However, negative factors such as rising interest rates could pressure financial stocks, and economic slowdowns might impact consumer-focused sectors like Consumer Defensive and Consumer Cyclical.
XMAG Top 10 Holdings
The Defiance Large Cap ex-Mag 7 ETF (XMAG) offers a refreshing take on large-cap investing by steering clear of the dominant tech giants, but technology still plays a role with Broadcom leading the charge thanks to its focus on AI semiconductors. Financials like JPMorgan Chase are steady contributors despite some challenges with credit costs, while Eli Lilly’s bullish momentum in healthcare adds a dose of growth potential. Oracle’s cloud-driven rally is a bright spot, though its high valuation raises eyebrows. With a U.S.-centric portfolio and a diverse sector mix, XMAG balances tech exposure with industrial and consumer staples, aiming for stability in a market often swayed by Big Tech.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Broadcom | 4.54% | $2.40M | $1.75T | 118.82% | 76 Outperform | |
| JPMorgan Chase | 2.20% | $1.16M | $855.50B | 39.55% | 70 Outperform | |
| Eli Lilly & Co | 1.86% | $985.53K | $815.73B | 5.36% | 76 Outperform | |
| Berkshire Hathaway B | 1.66% | $880.48K | $1.03T | 5.62% | 69 Neutral | |
| Visa | 1.53% | $809.10K | $656.47B | 17.20% | 75 Outperform | |
| Exxon Mobil | 1.29% | $681.26K | $487.54B | -0.51% | 79 Outperform | |
| Netflix | 1.20% | $634.89K | $474.10B | 47.98% | 69 Neutral | |
| Johnson & Johnson | 1.19% | $629.35K | $455.04B | 17.95% | 78 Outperform | |
| Mastercard | 1.18% | $624.00K | $495.83B | 8.64% | 69 Neutral | |
| Walmart | 1.16% | $615.63K | $806.69B | 23.10% | 75 Outperform |
XMAG Technical Analysis
Positive
―
Price Trends
22.06
Positive
21.63
Positive
20.78
Positive
Market Momentum
0.10
Positive
53.17
Neutral
40.30
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMAG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 22.29, equal to the 50-day MA of 22.06, and equal to the 200-day MA of 20.78, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 53.17 is Neutral, neither overbought nor oversold. The STOCH value of 40.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XMAG.
XMAG Peer Comparison
Comparison Results
Performance Comparison
XMAG
Defiance Large Cap ex-Mag 7 ETF
22.34
2.86
14.68%
ONEO
SPDR Russell 1000 Momentum Focus ETF
―
―
―
BCUS
Bancreek U.S. Large Cap ETF
―
―
―
UPSD
Aptus Large Cap Upside ETF
―
―
―
HUSV
First Trust Horizon Managed Volatility Domestic ETF
―
―
―
EGGY
NestYield Dynamic Income Shield ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents